Intellia Therapeutics is acquiring Rewrite Therapeutics, which is developing new tools for genome editing, including polymerase DNA recording. Intellia will pay $45 million and an additional $155 million when certain milestones are reached.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept